<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501149</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx2011-2</org_study_id>
    <nct_id>NCT01501149</nct_id>
  </id_info>
  <brief_title>Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ</brief_title>
  <acronym>CTTNKTL-Ⅲ/Ⅳ</acronym>
  <official_title>A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mingzhi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan TongJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Henan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of DDGP regiment&#xD;
      (gemcitabine，pegaspargase,cisplatin,dexamethasone) for patients with stage Ⅲ/Ⅳ Natural Killer&#xD;
      (NK)/T Cell Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with NK/T cell lymphoma usually have a bad prognosis. These patients cannot be&#xD;
      treated successfully with the conventional chemotherapy of CHOP. The investigators have been&#xD;
      proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy&#xD;
      regiment DDGP (gemcitabine，pegaspargase, cisplatin, dexamethasone) in the patients with stage&#xD;
      Ⅲ/Ⅳ NK/T cell lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>every 6 weeks,up to completion of treatment(approximately 18 weeks )</time_frame>
    <description>21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to the date of death (approximately 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median survival time</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Nasal and Nasal-type NK/T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>DDGP regiment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMILE Regiment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified SMILE （methotrexate，hexadecadrol，Ifosfamide，L-AsparaginaseL，Etoposide，Mesna）Regiment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)</intervention_name>
    <description>DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.</description>
    <arm_group_label>DDGP regiment</arm_group_label>
    <other_name>DDGP regiment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）</intervention_name>
    <description>MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.</description>
    <arm_group_label>SMILE Regiment</arm_group_label>
    <other_name>Modified SMILE regiment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time &gt; 3&#xD;
             months&#xD;
&#xD;
          -  Histological confirmed NK/T cell lymphoma&#xD;
&#xD;
          -  None of chemotherapy or radiotherapy has been previously used&#xD;
&#xD;
          -  None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L,&#xD;
             platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤&#xD;
             1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is&#xD;
             normal (Inclusion Criteria of 1,3,6 groups )&#xD;
&#xD;
          -  At least one measurable lesion&#xD;
&#xD;
          -  None of other serious diseases, cardiopulmonary function is normal&#xD;
&#xD;
          -  Pregnancy test of women at reproductive age must be negative&#xD;
&#xD;
          -  Patients could be followed up&#xD;
&#xD;
          -  None of other relative treatments including the traditional Chinese medicine,&#xD;
             immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic&#xD;
             treatments.&#xD;
&#xD;
          -  volunteers who signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disagreement on blood sample collection&#xD;
&#xD;
          -  Patients allergic of any of drug in this regimen or with metabolic disorder&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Serious medical illness likely to interfere with participation&#xD;
&#xD;
          -  Serious infection&#xD;
&#xD;
          -  Primitive or secondary tumors of central nervous system&#xD;
&#xD;
          -  Chemotherapy or radiotherapy contraindication&#xD;
&#xD;
          -  The evidence of CNS metastasis&#xD;
&#xD;
          -  History of peripheral nervous disorder or dysphrenia&#xD;
&#xD;
          -  patients participating in other clinical trials&#xD;
&#xD;
          -  patients taking other antitumor drugs&#xD;
&#xD;
          -  patients estimated to be unsuitable by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi Zhang, Pro，Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <phone>13838565629</phone>
    <email>mingzhi_zhang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <email>mingzhi_zhang@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Department of The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <email>mingzhi_zhang@126.com</email>
    </contact>
    <investigator>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>the director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <keyword>NK/T cell lymphoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>clinical trial</keyword>
  <keyword>RR</keyword>
  <keyword>PFS</keyword>
  <keyword>OS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

